^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PRT3789

    i
    Other names: PRT3789, PRT-SCA2, PRT-3789, PRT 3789
    Company:
    Prelude Therap
    Drug class:
    SMARCA2 degrader
    Related drugs:
    22h
    KEYNOTE-G02: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P2, N=6, Terminated, Prelude Therapeutics | Trial completion date: Dec 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Jan 2026; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    Keytruda (pembrolizumab) • PRT3789
    4ms
    PRT3789-01: PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=135, Completed, Prelude Therapeutics | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Oct 2025 | Trial primary completion date: Mar 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    docetaxel • PRT3789
    4ms
    PRT3789 is a First-in-Human SMARCA2-Selective Degrader that Induces Synthetic Lethality in SMARCA4-Mutated Cancers. (PubMed, Cancer Res)
    Together, these findings demonstrate the selective targeting of SMARCA2 and the potential for a favorable therapeutic index with PRT3789. Phase I/II clinical trials with PRT3789 are ongoing in biomarker-selected patients with SMARCA4-mutated solid tumors.
    P1 data • Journal • First-in-human
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    PRT3789
    5ms
    KEYNOTE-G02: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, Prelude Therapeutics | Recruiting --> Active, not recruiting | N=60 --> 7
    Enrollment closed • Enrollment change
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    Keytruda (pembrolizumab) • PRT3789
    7ms
    PRT3789-01: PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=135, Active, not recruiting, Prelude Therapeutics | Recruiting --> Active, not recruiting | N=226 --> 135
    Enrollment closed • Enrollment change
    |
    docetaxel • PRT3789
    1year
    KEYNOTE-G02: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P2, N=60, Recruiting, Prelude Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    Keytruda (pembrolizumab) • PRT3789
    1year
    A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Prelude Therapeutics
    New P2 trial
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    SMARCA4 mutation • SMARCA4 deletion
    |
    Keytruda (pembrolizumab) • PRT3789
    over1year
    PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=186, Recruiting, Prelude Therapeutics | N=118 --> 186
    Enrollment change • Combination therapy • Metastases
    |
    docetaxel • PRT3789
    almost2years
    PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=118, Recruiting, Prelude Therapeutics | N=86 --> 118
    Enrollment change • Combination therapy • Metastases
    |
    docetaxel • PRT3789
    over2years
    A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation (ESMO 2023)
    Secondary endpoints include objective response rate, progression-free survival, duration of response, disease control rate, and PK and PD profiles of PRT3789. The study began enrolling patients in January 2023.
    Clinical • P1 data • Metastases
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    SMARCA4 mutation
    |
    PRT3789
    3years
    A Study of PRT3789 in Participants With Select Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=86, Recruiting, Prelude Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    PRT3789
    3years
    A Study of PRT3789 in Participants With Select Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=86, Not yet recruiting, Prelude Therapeutics
    New P1 trial • Metastases
    |
    SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    PRT3789